RAS: Past, Present, and Future

1. A brief history of RAS and the RAS InitiativeFrank McCormick2. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutationsRachel A. Burge and G. Aaron Hobbs3. Drug targeting opportunities en route to Ras nanoclustersKarolina Pavic, Rohan Chippalkatti, and Daniel Abankwa4. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancerJ. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan-Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, and Channing J. Der5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stoneAlexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, and Gary A. Piazza6. Targeting RAS oncogenesis with SOS1 inhibitorsRoman Christian Hillig and Benjamin Bader7. Inhibition of SHP2 as an approach to block RAS-driven cancersYu-Ting Chou and Trever G. Bivona8. Targeting the "undruggable RAS with biologicsMichael Whaby, Imran Khan, and John P. O'Bryan9. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gainJonathan M. DeLiberty, Ryan Robb, Claire E. Gates, and Kirsten L. Bryant10. The RASopathies: Biology, genetics and therapeutic optionsJody Fromm Longo and Steven L. Carroll